TEL AVIV — February 9, 2026 — Leads & Copy — Entera Bio Ltd. (NASDAQ: ENTX) has appointed Geno J. Germano as Chairman of the Board, effective Feb. 4, 2026. Germano succeeds Gerald Lieberman, who is stepping down as Chairman.
The appointment follows a period of accelerating progress across Entera’s pipeline as the Company plans to advance two oral PTH peptide programs into clinical testing within 2026, a Phase 3 registrational study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism.
Germano is a pharmaceutical and life sciences executive with more than three decades of leadership experience spanning development, commercialization, and global operations. He held senior leadership roles at Pfizer, including as Group President of Pfizer’s Global Innovative Pharmaceutical Business, where he led the company’s approximately $14 billion innovative medicines portfolio with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas. From 2013 to February 2016, Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer.
From 2009 through 2013, Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets. Additionally, Germano has served on the board of directors of Precision Biosciences, Inc. since March 2020. In the past five years, Germano served on the boards of directors of Sage Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Germano received his B.S. in Pharmacy from Albany College of Pharmacy.
“Entera’s lead clinical asset, EB613, has the potential to fundamentally change how osteoporosis is treated,” said Germano. “While anabolic therapies are well established as highly effective, their use has largely been limited by the burden of injections. An oral anabolic therapy could move bone-building treatment earlier in the treatment paradigm and into frontline use for a much broader patient population. Combined with Entera’s plans for hypoparathyroidism and metabolic diseases, I look forward to working with the team as the Company enters this pivotal phase of development and execution.”
Miranda Toledano, Chief Executive Officer of Entera, thanked Lieberman for his contributions during his tenure on the board. She said the company is honored to welcome Germano as Chairman and that the last three years have set the foundation for Entera’s highly differentiated oral peptide pipeline, N-Tab® platform, regulatory alignment and transition to late-stage clinical testing. Toledano added that Germano’s decades of global biopharmaceutical leadership experience and proven ability to scale highly differentiated therapeutic platforms through late-stage development and toward commercialization will be a critical asset to Entera.
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
Source: Entera Bio
